Celon Pharma (CLN) Q2 2025 earnings summary

Executive summary

• Consolidated revenue for H1 2025 was PLN 105.9m, stable year-over-year, with growth in generics offset by a decline in innovative segment grants.

• EBITDA for generics rose to PLN 32.8m (+19.8% y/y), while innovative segment EBITDA loss deepened to PLN -43.8m.

• Net loss widened to PLN -58.1m from PLN -23.7m y/y, mainly due to lower grant income and sustained R&D investment.

• Cash position at June 30, 2025 was PLN 39m, down from PLN 75.1m at year-end, reflecting planned R&D outlays.

Financial highlights

• Revenue: PLN 105.9m (flat y/y); generics up, innovative segment down.

• EBITDA: Group -PLN 11m (vs. +PLN 0.5m y/y); generics PLN 32.8m (+19.8% y/y), innovative -PLN 43.8m.

• Net loss: PLN -58.1m (vs. -PLN 23.7m y/y); EPS: -1.08 PLN (vs. -0.44 PLN y/y).

• Cash and equivalents: PLN 39m (vs. PLN 75.1m at 2024 year-end).

Outlook and guidance

• Focus on expanding generics, especially Salmex, and advancing innovative pipeline.

• Plans to introduce at least two new clinical candidates annually and seek partners for late-stage assets.

• No formal financial guidance published for 2025.